AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weig, M.
Right arrow Articles by Müller, F.-M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weig, M.
Right arrow Articles by Müller, F.-M. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 966-968, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.966-968.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Synergism of Voriconazole and Terbinafine against Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis

Michael Weig1,2,* and Frank-Michael C. Müller3,4,*

Department of Bacteriology, University of Göttingen, Göttingen,1 and Institute for Hygiene and Microbiology,2 Department of Pediatrics,3 and Institute for Molecular Biology of Infection,4 University of Würzburg, Würzburg, Germany

Received 25 March 2000/Returned for modification 21 October 2000/Accepted 30 November 2000

The synergism of voriconazole (VRC) and terbinafine was studied by using 39 genotypically defined clinical Candida albicans isolates that were cross-resistant to fluconazole and VRC and serial isolates that gradually developed azole resistance. Synergy was noticed in 100% (eight of eight) of the strains that were resistant to VRC. Antagonism was not observed.

* Corresponding author. Mailing address for Michael Weig: Department of Bacteriology, University of Göttingen, Kreuzbergring 57, D-37075 Göttingen, Germany. Phone: 49-551397099. Fax: 49-551395861. E-mail: mweig{at}gwdg.de. Mailing address for F.-M. C. Müller: Department of Pediatrics, University of Würzburg, Josef-Schneider-Straße 2, D-97080 Würzburg, Germany. Phone: 49-931201-5831. Fax: 49-931201-5833. E-mail: fmmueller{at}mail.uni-wuerzburg.de.

Antimicrobial Agents and Chemotherapy, March 2001, p. 966-968, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.966-968.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.